SLDB Bears Add Into the Print — But Borrowing Stays Wide Open

Solid Biosciences reports today with short sellers holding their largest position in months — yet the options market and analyst community point firmly the other way.

Short interest is the defining tension heading into this print. Bears have added aggressively through July: the short position has climbed 26.4% in a single week and 31.3% over the past month, reaching 26.5% of the free float. The ORTEX short score has edged higher again, now at 70.9, its peak for the recent window. That is a genuinely elevated short position for a clinical-stage biotech at $8.71 — down 21% over the past month but up about 2.6% on the week. The borrow market, however, offers no sign of friction. Availability runs at roughly 227%, meaning more than two shares remain available for every one already borrowed, and cost to borrow has stayed low at 0.54% despite ticking up 25% on the week. Bears face no mechanical pressure. They are building, freely.

Options traders are reading the situation very differently. The put/call ratio sits at just 0.15, essentially in line with its 20-day average of 0.15 and close to the lowest readings of the past year — the z-score is near zero. Call volume dominates options activity, and that has been consistent for weeks. The picture is one of a stock where short sellers and options traders have taken opposing stances: bears have a large and growing position, while options flow reflects little demand for downside protection.

The analyst community sides with the bulls. All eight covering analysts carry buy-equivalent ratings, with a consensus mean target of $17.73 — implying roughly 104% upside from current levels. HC Wainwright raised its target to $25 in early June, the most recent action on record. The bull case centres on SGT-003 for Duchenne muscular dystrophy and a cash runway extending into the first half of 2028, which limits near-term dilution risk. Bears counter that gene therapy execution timelines are unpredictable and that DMD competition from Sarepta Therapeutics and others narrows the addressable prize. Institutional ownership is notably concentrated: RA Capital and Perceptive Advisors together hold roughly 24% of shares, and several other specialist biotech funds added materially in the first half of the year — a base that could amplify moves in either direction.

Today's print will test whether clinical progress on SGT-003 and the broader pipeline warrants re-rating the stock back toward analyst targets, or whether the bears who have been steadily building their position through July are positioned ahead of a disappointment.